Payment overview · 2025
General Payments
$36.17
2 reported records · 2 companies
Healthcare provider profile · identity verified
Brian Cross, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · GRIFFIN, GA · NPI 1720082613
Verified facts
What the public records show
CMS Open Payments records show Brian Cross, M.D. received $36.17 in general payments during 2025 across 2 reported records.
GlaxoSmithKline, LLC. accounted for 57.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Shingrix.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.77 | 57.4% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$15.40 | 42.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $36.17 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $20.77 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $20.77 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $15.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
75 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 849 | 245 |
| Amlodipine Besylate | Amlodipine Besylate | 548 | 143 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 382 | 104 |
| Tramadol Hcl | Tramadol Hcl | 341 | 79 |
| Pantoprazole Sodium | Pantoprazole Sodium | 335 | 91 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 317 | 82 |
| Omeprazole | Omeprazole | 302 | 79 |
| Metformin Hcl | Metformin Hcl | 251 | 76 |
| Lisinopril | Lisinopril | 243 | 74 |
| Gabapentin | Gabapentin | 242 | 60 |
| Levothyroxine Sodium | Levothyroxine Sodium | 239 | 77 |
| Metoprolol Succinate | Metoprolol Succinate | 215 | 60 |
| Zolpidem Tartrate | Zolpidem Tartrate | 210 | 46 |
| Losartan Potassium | Losartan Potassium | 209 | 65 |
| Simvastatin | Simvastatin | 206 | 50 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 194 | 44 |
| Alprazolam | Alprazolam | 193 | 38 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 157 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 156 | 50 |
| Jardiance | Empagliflozin | 152 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 150 | 49 |
| Fluticasone Propionate | Fluticasone Propionate | 142 | 42 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 142 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 135 | 33 |
| Trazodone Hcl | Trazodone Hcl | 134 | 25 |
| Allopurinol | Allopurinol | 132 | 38 |
| Famotidine | Famotidine | 129 | 40 |
| Tizanidine Hcl | Tizanidine Hcl | 129 | 25 |
| Glimepiride | Glimepiride | 127 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 124 | 31 |
| Meloxicam | Meloxicam | 124 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 121 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 121 | 36 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 120 | 27 |
| Farxiga | Dapagliflozin Propanediol | 118 | 31 |
| Furosemide | Furosemide | 117 | 35 |
| Ezetimibe | Ezetimibe | 114 | 31 |
| Potassium Chloride | Potassium Chloride | 113 | 28 |
| Montelukast Sodium | Montelukast Sodium | 112 | 30 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 112 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 107 | 31 |
| Synthroid | Levothyroxine Sodium | 105 | 24 |
| Carvedilol | Carvedilol | 100 | 35 |
| Eliquis | Apixaban | 98 | 27 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 98 | 20 |
| Glipizide Er | Glipizide | 92 | 20 |
| Ozempic | Semaglutide | 92 | 24 |
| Celecoxib | Celecoxib | 87 | 25 |
| Prednisone | Prednisone | 85 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 81 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 81 | 21 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 81 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 79 | 23 |
| Sertraline Hcl | Sertraline Hcl | 79 | 18 |
| Buspirone Hcl | Buspirone Hcl | 78 | 15 |
| Clonidine Hcl | Clonidine Hcl | 78 | 20 |
| Metformin Hcl Er | Metformin Hcl | 78 | 23 |
| Pregabalin | Pregabalin | 75 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 75 | 18 |
| Trulicity | Dulaglutide | 73 | 13 |
| Valsartan | Valsartan | 70 | 16 |
| Mounjaro | Tirzepatide | 67 | 11 |
| Clonazepam | Clonazepam | 63 | 18 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 60 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 60 | 13 |
| Ibuprofen | Ibuprofen | 58 | 17 |
| Meclizine Hcl | Meclizine Hcl | 58 | 17 |
| Repatha Sureclick | Evolocumab | 58 | 11 |
| Januvia | Sitagliptin Phosphate | 57 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 55 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 53 | 18 |
| Diazepam | Diazepam | 52 | 12 |
| Donepezil Hcl | Donepezil Hcl | 51 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 51 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 49 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 48 | suppressed |
| Memantine Hcl | Memantine Hcl | 45 | suppressed |
| Atenolol | Atenolol | 44 | 13 |
| Finasteride | Finasteride | 44 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 20 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 43 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 42 | 25 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 42 | 12 |
| Xarelto | Rivaroxaban | 42 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 41 | 11 |
| Levetiracetam | Levetiracetam | 41 | suppressed |
| Myrbetriq | Mirabegron | 41 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 39 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 39 | 12 |
| Estradiol | Estradiol | 39 | 11 |
| Nifedipine Er | Nifedipine | 39 | 13 |
| Bupropion Xl | Bupropion Hcl | 38 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 37 | suppressed |
| Mirtazapine | Mirtazapine | 37 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 36 | suppressed |
| Glipizide | Glipizide | 35 | 11 |
| Risperidone | Risperidone | 34 | suppressed |
| Topiramate | Topiramate | 34 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 34 | 11 |
| Fluconazole | Fluconazole | 33 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Rybelsus | Semaglutide | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | 12 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 28 | suppressed |
| Methocarbamol | Methocarbamol | 28 | suppressed |
| Lorazepam | Lorazepam | 27 | 15 |
| Baclofen | Baclofen | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Novolog Flexpen | Insulin Aspart | 26 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 25 | suppressed |
| Lamotrigine | Lamotrigine | 25 | suppressed |
| Methylprednisolone | Methylprednisolone | 24 | 23 |
| Sucralfate | Sucralfate | 24 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 22 | suppressed |
| Ibu | Ibuprofen | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 21 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 21 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 21 | suppressed |
| Brilinta | Ticagrelor | 20 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 19 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | 14 |
| Sildenafil Citrate | Sildenafil Citrate | 19 | suppressed |
| Azithromycin | Azithromycin | 18 | 14 |
| Cefuroxime | Cefuroxime Axetil | 18 | 15 |
| Febuxostat | Febuxostat | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Sulfasalazine | Sulfasalazine | 18 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 18 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | suppressed |
| Lacosamide | Lacosamide | 17 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 14 |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Fentanyl | Fentanyl | 15 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 13 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 12 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Captopril | Captopril | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Prolia | Denosumab | 11 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 11 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $36.17 · 2 records | GlaxoSmithKline, LLC. | AREXVY, MINIMED 780G, SHINGRIX | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Shingrix play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error